Professor Kenneth Chien has been an Advisor to EQT since 2020.
Kenneth is a Co-Founder of Moderna Therapeutics, and has served as a senior consultant and advisory board member to several biotechnology and large pharmas, including Genentech, Roche, GSK, Wyeth, and Pfizer. In addition, he served for over a decade on the SAB of the Pictet et Cie Biotech Fund, based in Geneva. Kenneth was also a co-founder of the Institute of Molecular Medicine at Peking University, currently the premier site for cardiovascular science in China. In addition, he has co-founded several biotechnology newcos in the Stockholm region, in collaboration with SWIB, a Swedish based biotech equity group.
Kenneth is a third generation Harvard alumnus (F.S. Chien ´10, HBS ’12; L.C. Chien ’45) and graduated from Harvard College in 1973. He earned his MD in 1980 and PhD in 1983 from Temple University in Pennsylvania, and internship, residency, and cardiology fellowship training at the University of Texas Southwestern Medical School in Dallas. Subsequently, he became the Director of the UCSD Institute of Molecular Medicine and directed the joint UCSD-Salk Institute NIH Molecular Medicine Training Program. Kenneth received a Presidential appointment as a Professor to Karolinska Institutet,
in 2013, previously he was the Charles and Elizabeth Ann Sanders Professor in the Department of Stem Cell and Regenerative Biology at Harvard University.